Suffering from cystic fibrosis and rejecting the transplanted lungs he had gotten just two years ago, Jon Sacker, 33, came to UPMC in Pittsburgh from his hometown in Moore, Oklahoma, as a last resort. But when his carbon dioxide levels spiked, he became too sick to be immediately relisted for transplant. He was also too … Continued
We are honored to have the Hemolung RAS recognized as a finalist for the 2014 MDEA Awards. This admission is the result of more than 10 years of dedication and perseverance on the part of our staff, investors, and clinical collaborators who all share a common vision: A better future for patients suffering from acute … Continued
Last year was a banner year for South Side-based ALung Technologies. The local life sciences firm received CE Mark approval and entered select European markets with its Hemolung Respiratory Assist System (RAS), raised a $15.8-million Series B-1 round to support the product launch, and was named the Life Sciences Company of the Year by the Pittsburgh Technology Council’s Tech 50 Awards.
Acute respiratory failure is not uncommon and can occur from a variety of causes to people of all ages. Chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS) are just two of many reasons why a patient may experience respiratory failure and require invasive mechanical ventilation (IMV). Approximately 13.7 million people in the United States are living with COPD, and ARDS averages approximately 160,000 cases per year. While IMV has proven to be an indispensible therapy for persons undergoing such incidents, an increased understanding of further lung injury that can in fact be caused by the ventilator has led to a shift in the paradigms for providing respiratory support. A new device offers a minimally invasive option for respiratory support that may allow patients to either avoid IMV or mitigate its injurious side effects.
ALung chairman & CEO Peter DeComo talks about advances in respiratory therapy and his company’s Hemolung respiratory system.
As it pushes toward a larger commercial rollout in Europe and other markets, respiratory device maker ALung Technologies Inc. has raised a $15.8 million Series B-1 round, the Pittsburgh company announced. The funding was provided by new investors Allos Ventures and West Capital Partners, joined by returning investors Birchmere Ventures , BlueTree Capital Group, Pittsburgh Life Sciences Greenhouse, Smithfield Trust Co. and … Continued
Like most medical device executives, Peter DeComo, chairman/CEO of ALung Technologies (Pittsburgh), a developer of respiratory assist devices, knows how difficult it can be to attract investors in the current environment. But with the right strategy and a differentiating technology, raising money is not impossible. ALung proved that with its recently closed $15.8 million Series B-1 financing … Continued
Pittsburgh-based ALung Technologies has closed on a $15.8 million Series B-1 financing round, one of the largest financings in the region’s life sciences industry. Source: Pittsburgh Business Times
Pittsburgh’s ALung Technologies wrapped up a $15.8 million round of new financing, money that will back a broader global rollout of its lung-assist device. The new Series B-1 financing round reaffirms an ongoing trend in medical device industry venture financing. Companies these days are more likely to win financial backing when they have a product … Continued
ALung Technologies raises a nearly $16 million Series B1 round for its Hemolung respiratory assist device. ALung Technologies said it raised a $15.8 million Series B1 round it plans to use to accelerate the commercialization of its Hemolung respiratory assist device. The Pittsburgh-based medical device company said the round was led by Allos Ventures and included … Continued